You are here
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
improving Cas9 mediated homologous recombination in pluripotent stem cellsSBC: Applied Stemcell, Inc. Topic: 200
DESCRIPTION provided by applicant Gene correction therapy is one of the most important application directions in regenerative medicine Scientists are exploring various approaches to introduce targeted mutations corrections to pluripotent stem cells PSCs to establish disease models and or to develop therapeutic agents Emerging technologies such as Zinc Finger Nucleases ZFNs Transcription ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
An epitope focused nanoparticle vaccine for MRSA and biodefenseSBC: VLP BIOTECH, INC. Topic: NIAID
DESCRIPTION provided by applicant Overall Staphylococcus aureus is a gram positive bacteria which possesses a multitude of virulence factors It is a frequent and severe pathogen in hospitals and of increasing concern in the community where it results in severe skin infections pneumonia bacterial endocarditis and sepsis A significant proportion of these infections are the result of methici ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatmentSBC: BIOVINC, LLC Topic: NIDCR
DESCRIPTION provided by applicant Infectious bone disease is a major cause of morbidity and mortality worldwide Successful treatment often requires surgical intervention with longer term antibiotic therapy Bacterial biofilm pathogens are associated with most osseous infections and represent a major target of therapy The biofilm pathogens associated with chronic bone infections bind to and co ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
Urocortin Gene Transfer for CHF a Paracrine Approach Using Intravenous AAVSBC: Renova Therapeutics, Inc. Topic: NHLBI
DESCRIPTION provided by applicant Gene transfer for the treatment of cardiovascular diseases is bedeviled by inability to obtain safely and easily sufficient cardiac transgene expression Current methods of gene transfer for heart disease include intramuscular injection into heart muscle or intracoronary delivery approaches that are cumbersome to apply Consequently we have considered the u ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health